Status:
RECRUITING
Immune Registry for BK in Kidney Transplant Recipients
Lead Sponsor:
Virginia Commonwealth University
Collaborating Sponsors:
Eurofins
Conditions:
BK Virus Infection
Kidney Transplant; Complications
Eligibility:
All Genders
18+ years
Brief Summary
Kidney transplantation (KT) is the best treatment modality available to date for patients with advanced kidney disease and the success of KT is dependent on maintaining a selective intricate balance b...
Detailed Description
As with other viral infections, adaptive immunity plays an essential role in the control of BK virus infection. Previous studies have shown that humoral immunity doesn't prevent viral reactivation and...
Eligibility Criteria
Inclusion
- Adult (\>18 years old) male and female, deceased donor KT recipients
- Will include single organ transplants.
- Each participant must also have recently been diagnosed with BK viremia.
- In addition to the aforementioned inclusion criteria, each participant in the sub-study must also have recently been diagnosed with BK viremia or have difficult-to-treat BKV \> 3 logs (BKV log does not decrease by more than 1 log copy/ml drop on second per protocol lab).
Exclusion
- Prisoners will not be included in the study
- Multi-organ transplants and pregnant women
Key Trial Info
Start Date :
May 29 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06538961
Start Date
May 29 2024
End Date
May 1 2026
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298